Progress of bortezomib in children with relapsed/refractory B-cell acute lymphoblastic leukemia
Acute lymphoblastic leukemia(ALL)is the most common pediatric cancer and has good outcome.However,the prognosis of relapsed/refractory ALL in children is poor.Intensive reinduction chemotherapy and hematopoietic stem cell transplantation have become alternative treatments.Bortezomib,as the primary generation proteasome inhibitor,has been approved for the treatment of multiple myeloma and mantle cell lymphoma.In recent years,several clinical studies have confirmed promising responses and well tolerated of bortezomib combined with various chemotherapeutic drugs in treating children with relapsed/refractory ALL,to improve the complete remission rate and survival rate.This article reviews the mechanisms of bortezomib in ALL and the clinical study progress and safety of bortezomib combined with chemotherapy in children with relapsed/refractory ALL.
NETL
NSTL
万方数据
